补肾益气活血法对前列腺增生尿流动力学的临床及实验研究
|
摘要
目的:通过观察益肾通胶囊治疗BPH的临床疗效及对尿流动力学等指标的影响,探索能综合调节前列腺形态及膀胱逼尿肌、膀胱颈括约肌功能的药物;并通过动物试验,探讨益肾通方中单味中药广王不留行醇提物大鼠慢性膀胱颈梗阻模型平滑肌凋亡细胞的影响及对大鼠慢性膀胱颈梗阻模型逼尿肌半定量逆转录聚合酶链式反应(RT-PCR)法检测平滑肌肌球蛋白的表达的影响,探讨广王不留行醇提物在影响平滑肌细胞分子病理学改变方面的作用及意义,推测其治疗BPH的机理,为进一步应用和开发祖国传统中医药提供现代科学理论依据。
方法:本课题由临床研究和动物实验两部分组成。临床研究部分采用前瞻性随机对照方法,以非那雄胺为对照组,进行治疗组和对照组治疗前后自身对照和组间对照的研究。研究对象来源于广州中医药大学第一附属医院泌尿男科门诊及住院患者,共60例,两组患者一般资料和实验室指标经统计学分析无显著性差异,具有可比性,并将其随机分为治疗组40例,对照组20例。治疗组给予益肾通胶囊,每次4粒,每日3次,对照组给予非那雄胺,每次1粒(5mg),每日1次,疗程共3个月。观察两组治疗前后I-PSS评分、前列腺体积、膀胱残余尿、最大尿流率及膀胱逼尿肌收缩力等指标。动物实验部分选择普通级SD雄性大鼠45只,随机分为空白组、造模组、实验组各15只。参照文献资料制作大鼠膀胱颈梗阻模型,药物应用广王不留行醇提取液(广王不留行为益肾通中主要药物之一)。其中空白组未进行造模而给药灌胃,造模组造模不给物,实验组造模并给药。应用TUNEL法检测大鼠慢性膀胱颈梗阻模型逼尿肌平滑肌凋亡细胞及其广王不留行醇提物对其影响;通过半定量逆转录聚合酶链式反应(RT-PCR)法检测平滑肌肌球蛋白的表达。所有数据用spss11.0软件包进行统计分析。
结果:临床研究部分:治疗组的综合疗效与对照组相比有统计学差异(P＜0.05)。与治疗前相比,治疗组与对照组在I-PSS评分、最大尿流率方面,分别为P＜0.01和P＜0.05,均有统计学差异,而前者更显著;在膀胱残余尿和膀胱逼尿肌收缩力方面,治疗组为P＜0.05、P＜0.01,有统计学差异,而对照组无统计学差异(P＞0.05);在前列腺体积方面,两组均与治疗无统计学差异(P＞0.05)。与对照组相比,治疗组I-PSS评分、膀胱残余尿、最大尿流率、膀胱逼尿肌收缩力方面均有统计学差异(P＜0.05);对前列腺体积改变两组均无统计学差异(P＞0.05)。动物实验部分:(1)镜下空白组凋亡细胞数目为15.5%,造模组凋亡细胞数目为50.2%,实验组凋亡细胞数目为30.4%,各组相比均有统计学意义(p＜0.05)。(2)电泳鉴定结果空白组条带最清晰,造模组最弱,而实验组介于两者之间。
结论:本课题应用益肾通胶囊治疗BPH的临床疗效优于对照组并在改善I-PSS评分、膀胱残余尿、最大尿流率和膀胱逼尿肌收缩力方面具有较明显的优势,推测益肾通方治疗BPH的机理存在多方面的综合的作用机理,既能够改善慢性膀胱颈梗阻症状也能提高膀胱逼尿肌功能,为BPH的治疗提供了新的思路。动物实验提示广王不留行醇提物可以抑制大鼠慢性膀胱颈梗阻模型膀胱逼尿肌平滑肌细胞凋亡和平滑肌细胞的退化状态,从而改善逼尿肌功能。
Objective: To observe the treatment of BPH of Yishentong capsule and the clinical effect on urodynamic indicators such as the impact of exploration can be integrated form of regulation and detrusor prostate, bladder neck sphincter function of the drug, and through animal testing, of Yishentong Arguably the GuangWangBuLiuXing (Ficus Pumila L) to alcohol extracts of rat model of chronic bladder neck obstruction apoptosis smooth muscle cells of rats and chronic bladder neck obstruction model detrusor semi-quantitative reverse transcription-polymerase chain reaction (RT - PCR) testing of the smooth muscle myosin expression of on-line-do not stay in the influence of alcohol extract of molecular pathology smooth muscle cells to change the role and significance, its treatment of BPH speculate the mechanism for application and further development of the motherland Traditional Chinese medicine in the provision of modern scientific theory.
Methods: The subjects from clinical studies and animal experiments composed of two parts. Clinical studies of the use of randomized controlled forward-looking approach to non-finasteride for the control group, treatment and control groups before and after treatment self-control and the control group study. Study from the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine surgery department and andrology clinics and patients, a total of 60 cases, two groups of patients with general information and laboratory analysis of statistical indicators, as no significant difference, comparable, and were randomly divided into For the treatment group of 40 patients, 20 cases of the control group. The treatment group to Yishentong capsule, four capsule each, tid, the control group to finasteride, (5 mg), a day, a total of three months of treatment. Observation of the two groups before and after the treatment I-PSS score, prostate volume, bladder residual urine, the largest flow rate and detrusor contraction, and other indicators. Some animal experiments choose general-level SD 45 male lab rats were divided into the blank group, the model group, and the experimental group of 15 each. Reference to literature produced in the bladder neck obstruction model, the application of Chinese Medicine call GuangWangBuLiuXing (Ficus Pumila L)liquid (main medicine of Yishentong capsule). Blank group model and the administration gavage, the model of model not to the experimental group of modeling and administration. GuangWangBuLiuXing (Ficus Pumila L) observed to remain alcohol extract of the rat model of chronic bladder neck obstruction and detrusor contraction organizations and the morphology of apoptosis detrusor smooth muscle cells seizure (TUNEL). Spss11.0 package with all the data for statistical analysis. Results: The clinical study: the comprehensive effect of the treatment group compared with the control group a significant difference (P<0.05). Compared with before treatment, the treatment group and control group in the I-PSS score, the largest flow rate, respectively, P <0.01 and P <0.05, both significant difference, while the former more visible; residual urine in the bladder and bladder Detrusor contraction, the treatment group for the P<0.05, P<0.01, a significant difference, but no significant difference in the control group (P>0.05); in prostate volume, both groups with no significant difference in treatment (P>0.05). Compared with the control group, treatment group I-PSS score, bladder residual urine, the largest flow rate, the detrusor contraction in both statistical difference (P<0.05); prostate volume of the two groups had no statistical change Differences (P>0.05). Animal experiments: (1) under the number of blank group apoptosis of 15.5 percent, the model number of apoptosis 50.2 percent, the experimental group apoptosis number was 30.4 percent, compared to the group were statistically significant ( p<0.05). (2) electrophoretic analysis of the results of the blank group with the most clarity, the model weakest, and between the experimental group between the two.
Conclusion: The subject of Yishen capsule treatment of BPH clinical efficacy than the control group and to improve the I-PSS score, bladder residual urine, the largest flow rate and detrusor contraction has obvious advantages, benefits to speculate Kidney-treatment of BPH, the existence of the multi-faceted and integrated mechanism, both to improve the symptoms of chronic bladder neck obstruction can also improve the detrusor function, for the treatment of BPH provide a new way of thinking. GuangWangBuLiuXing(Ficus Pumila L) for animal experiments suggested that alcohol does not stay in line extract can inhibit the rat model of chronic bladder neck obstruction detrusor smooth muscle apoptosis and degraded state of the smooth muscle cells, thereby improving the detrusor function.
方法:本课题由临床研究和动物实验两部分组成。临床研究部分采用前瞻性随机对照方法,以非那雄胺为对照组,进行治疗组和对照组治疗前后自身对照和组间对照的研究。研究对象来源于广州中医药大学第一附属医院泌尿男科门诊及住院患者,共60例,两组患者一般资料和实验室指标经统计学分析无显著性差异,具有可比性,并将其随机分为治疗组40例,对照组20例。治疗组给予益肾通胶囊,每次4粒,每日3次,对照组给予非那雄胺,每次1粒(5mg),每日1次,疗程共3个月。观察两组治疗前后I-PSS评分、前列腺体积、膀胱残余尿、最大尿流率及膀胱逼尿肌收缩力等指标。动物实验部分选择普通级SD雄性大鼠45只,随机分为空白组、造模组、实验组各15只。参照文献资料制作大鼠膀胱颈梗阻模型,药物应用广王不留行醇提取液(广王不留行为益肾通中主要药物之一)。其中空白组未进行造模而给药灌胃,造模组造模不给物,实验组造模并给药。应用TUNEL法检测大鼠慢性膀胱颈梗阻模型逼尿肌平滑肌凋亡细胞及其广王不留行醇提物对其影响;通过半定量逆转录聚合酶链式反应(RT-PCR)法检测平滑肌肌球蛋白的表达。所有数据用spss11.0软件包进行统计分析。
结果:临床研究部分:治疗组的综合疗效与对照组相比有统计学差异(P＜0.05)。与治疗前相比,治疗组与对照组在I-PSS评分、最大尿流率方面,分别为P＜0.01和P＜0.05,均有统计学差异,而前者更显著;在膀胱残余尿和膀胱逼尿肌收缩力方面,治疗组为P＜0.05、P＜0.01,有统计学差异,而对照组无统计学差异(P＞0.05);在前列腺体积方面,两组均与治疗无统计学差异(P＞0.05)。与对照组相比,治疗组I-PSS评分、膀胱残余尿、最大尿流率、膀胱逼尿肌收缩力方面均有统计学差异(P＜0.05);对前列腺体积改变两组均无统计学差异(P＞0.05)。动物实验部分:(1)镜下空白组凋亡细胞数目为15.5%,造模组凋亡细胞数目为50.2%,实验组凋亡细胞数目为30.4%,各组相比均有统计学意义(p＜0.05)。(2)电泳鉴定结果空白组条带最清晰,造模组最弱,而实验组介于两者之间。
结论:本课题应用益肾通胶囊治疗BPH的临床疗效优于对照组并在改善I-PSS评分、膀胱残余尿、最大尿流率和膀胱逼尿肌收缩力方面具有较明显的优势,推测益肾通方治疗BPH的机理存在多方面的综合的作用机理,既能够改善慢性膀胱颈梗阻症状也能提高膀胱逼尿肌功能,为BPH的治疗提供了新的思路。动物实验提示广王不留行醇提物可以抑制大鼠慢性膀胱颈梗阻模型膀胱逼尿肌平滑肌细胞凋亡和平滑肌细胞的退化状态,从而改善逼尿肌功能。
Objective: To observe the treatment of BPH of Yishentong capsule and the clinical effect on urodynamic indicators such as the impact of exploration can be integrated form of regulation and detrusor prostate, bladder neck sphincter function of the drug, and through animal testing, of Yishentong Arguably the GuangWangBuLiuXing (Ficus Pumila L) to alcohol extracts of rat model of chronic bladder neck obstruction apoptosis smooth muscle cells of rats and chronic bladder neck obstruction model detrusor semi-quantitative reverse transcription-polymerase chain reaction (RT - PCR) testing of the smooth muscle myosin expression of on-line-do not stay in the influence of alcohol extract of molecular pathology smooth muscle cells to change the role and significance, its treatment of BPH speculate the mechanism for application and further development of the motherland Traditional Chinese medicine in the provision of modern scientific theory.
Methods: The subjects from clinical studies and animal experiments composed of two parts. Clinical studies of the use of randomized controlled forward-looking approach to non-finasteride for the control group, treatment and control groups before and after treatment self-control and the control group study. Study from the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine surgery department and andrology clinics and patients, a total of 60 cases, two groups of patients with general information and laboratory analysis of statistical indicators, as no significant difference, comparable, and were randomly divided into For the treatment group of 40 patients, 20 cases of the control group. The treatment group to Yishentong capsule, four capsule each, tid, the control group to finasteride, (5 mg), a day, a total of three months of treatment. Observation of the two groups before and after the treatment I-PSS score, prostate volume, bladder residual urine, the largest flow rate and detrusor contraction, and other indicators. Some animal experiments choose general-level SD 45 male lab rats were divided into the blank group, the model group, and the experimental group of 15 each. Reference to literature produced in the bladder neck obstruction model, the application of Chinese Medicine call GuangWangBuLiuXing (Ficus Pumila L)liquid (main medicine of Yishentong capsule). Blank group model and the administration gavage, the model of model not to the experimental group of modeling and administration. GuangWangBuLiuXing (Ficus Pumila L) observed to remain alcohol extract of the rat model of chronic bladder neck obstruction and detrusor contraction organizations and the morphology of apoptosis detrusor smooth muscle cells seizure (TUNEL). Spss11.0 package with all the data for statistical analysis. Results: The clinical study: the comprehensive effect of the treatment group compared with the control group a significant difference (P<0.05). Compared with before treatment, the treatment group and control group in the I-PSS score, the largest flow rate, respectively, P <0.01 and P <0.05, both significant difference, while the former more visible; residual urine in the bladder and bladder Detrusor contraction, the treatment group for the P<0.05, P<0.01, a significant difference, but no significant difference in the control group (P>0.05); in prostate volume, both groups with no significant difference in treatment (P>0.05). Compared with the control group, treatment group I-PSS score, bladder residual urine, the largest flow rate, the detrusor contraction in both statistical difference (P<0.05); prostate volume of the two groups had no statistical change Differences (P>0.05). Animal experiments: (1) under the number of blank group apoptosis of 15.5 percent, the model number of apoptosis 50.2 percent, the experimental group apoptosis number was 30.4 percent, compared to the group were statistically significant ( p<0.05). (2) electrophoretic analysis of the results of the blank group with the most clarity, the model weakest, and between the experimental group between the two.
Conclusion: The subject of Yishen capsule treatment of BPH clinical efficacy than the control group and to improve the I-PSS score, bladder residual urine, the largest flow rate and detrusor contraction has obvious advantages, benefits to speculate Kidney-treatment of BPH, the existence of the multi-faceted and integrated mechanism, both to improve the symptoms of chronic bladder neck obstruction can also improve the detrusor function, for the treatment of BPH provide a new way of thinking. GuangWangBuLiuXing(Ficus Pumila L) for animal experiments suggested that alcohol does not stay in line extract can inhibit the rat model of chronic bladder neck obstruction detrusor smooth muscle apoptosis and degraded state of the smooth muscle cells, thereby improving the detrusor function.
引文
[1]李飞,蔡惠明.良性前列腺增生治疗药物研究进展.药学进展,1995,19(4):193
[2]徐积恩.良性前列腺增生治疗药依普甾胺(Epristeride).国外医学·合成药、生化药制剂分册.1995.16(4):240
[3]焦安钦,前列腺增生症病机特点与治疗思路贵阳中医学院学报,1996:18(4):4
[4]周家珩.扶正化瘀法治疗前列腺增生症135例 江苏中医,1991;12(3):115
[5]杜英博.冯老治疗老年病经验点滴 实用中医内科杂志,1992:6(4):184
[6]何清湖.前列腺增生症肾虚血瘀病机探讨 湖南中医学院学报,1997:17(2)8-10
[7]祁公任,陈涛.前列腺增生症中医病机证治观[J].江苏中医,1998,19(11):16
[8]焦安钦.前列腺增生症病机特点与治疗思路[J].贵阳中医学院学报,1996,18(4):4
[9]林君玉.85例前列腺肥大症临床经验[J].江苏中医,1990,11(11):494
[10]张缃,卡金梅,王娟娥.中西医结合治疗老年前列腺良性肥大急性尿潴留[J].山西医学院学报,1993,4(2):231
[11]周家珩.扶正化痰法治疗前列腺增生症135例[J].江苏中医,1991,12(3):115
[12]杜英博.冯老治疗老年病经验点滴[J].实用中医内科杂志,1992,6(4):184
[13]张锡君.对老年前列腺肥大防治的体会[J].中医杂志,1986,27(5):330
[14]吴光明,魏秋关.清热利湿化瘀法治疗前列腺肥大33例[J].湖南中医杂志,1993,9(3):36
[15]何红兵,从瘀辨证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3):181。
[16]韦淑平,鞠祥宗.益肾通癃方治疗前列腺增生50例[J].陕西中医,2002,23(4):317.
[17]谢嘉文,沈自尹,王文健,等.补肾益元法与化瘀散结法治疗前列腺肥大症的临床研究[J].中国中西医结合杂志,1994,14(9):519
[18]张亚大,卢子杰,张平,黄树纲.益肾逐瘀汤治疗前列腺增生症30例观察[J].南京中医药大学学报(自然科学版),2001,17(4):216.
[19]张关荣.从瘀辨治前列腺增生症52例[J]、四川中医,1998.16(3):24.
[20]胡臻.升阳通络汤治疗前列腺增生症20例[J].中国中医药信息杂志,2002,9(9):53
[21]蓝毕生.通补奇经方治疗良性前列腺增生症32例[J].吉林中医药,2002,22(3)19.
[22]郭明福.“开利散结汤”治疗前列腺增生110例[J].江苏中医药,2003,2 4(3):34.
[23]赵建业.戴春福教授以活血法治疗前列腺增生症经验[J].福建中医药,2004,35(2):21-22.
[24]穆惠荣,路继儒.海藻玉壶汤加减治疗前列腺增生症(附26例分析)[J].医学理论与实践,2003,16(6):674.
[25]赵跃红.加味壮元汤治疗前列腺增生症62例[J]湖南中医杂志,2004,20(3):54.
[26]崔学教,王玺坤,丘振文.良性前列腺增生症的辨证论治[J].新中医,2002,34(4):3-4.
[27]德永固三.前列腺增生的汉方治疗[J].国外医学·中医中药分册,1997,19(4):41-44
[28]尹国良,李世平,邵俊.前列腺增生症的辨治体会[J]湖北中医杂志,2003,25(9):21.22.
[29]曹继刚,段臀志.辨证分型治疗前列腺增生93例疗效观察[J].云南中医中药杂志,2003,24(2):21.
[30]王劲松.自拟癃闭方治疗前列腺增生症50例[J].国医论坛,1997,12(1):32-34
[31]吴敬农.补敛提汤治疗老年前列腺肥大症64例[J].江苏中医,1996,17(1):17-18
[32]马华.癃闭通治疗老年前列腺增生症临床疗效观察[J].中医药研究,1996,16(2):29-30
[33]张庆好.启癃汤治疗老年前列腺肥大症55例[J].新中医,1995,27(2):23-24
[34]张云程.中药治疗前列腺增生症90例[J].成都中医学院学报,1991,(13):16-18
[35]姚德鸿.前列腺增生症[M].上海:上海医科大学出版社,1993.56
[36]梁永,董杨颖,张妍燕.肩闭通关汤治疗良性前列腺增生症33例疗效观察[J].河jE中医,2003,25(8):620.622.
[37]姜杰,周健民.中医药疗法治疗前列腺增生症80例临床观察[J].长春中医学院学报。2003,19(2):19.
[38]欧亚龙,杨光,下红静.消积通关汤治疗前列腺增生症62例疗效观察[J].四川中医,2004,22(6):49.51.
[39]宋晓鸿,陈氏前列安治疗前列腺增生症73例疗效观察[J].青海医药杂志,2004,34(10):45.46.
[40]李跃庆.宣降益气通癃汤治疗老年前列腺增生42例[J].实用中医内科杂志,2004,18(6):537.
[41]王敬善.前列舒丸治疗前列腺增生症和慢性前列腺炎81例[J].山东中医杂志,1990,9(6):12-13
[42]黄窈勤.前列舒丸的临床疗效观察[J].中成药,1993,15(3):23-24
[43]贾玉森.前列平治疗前列腺增生症的临床观察[J].中国医药学报,1996,16(1):5-7
[44]成爱光.中药注射液静脉滴注治疗前列腺增生症52例[J].上海中医药杂志,1999,(2):18-19
[45]唐涌志.癃闭舒胶囊治疗前列腺增生症的临床观察[J].上海中医药杂志,1999,(2):18-19
[46]金杰.生长因子抑制剂治疗前列腺增生症[J].中华泌尿外科杂志,1997,18(5):293
[47]柯梦笔.前列平治疗前列腺增生症46例.山东中医杂志.1995、14(2):542
[48]段登志.欧阳虹.王寅.等.前列回春胶囊治疗前列腺增生症56例.云南中医杂志.1994.15(6):35
[49]段登志,欧阳虹,王寅.等.前列回春胶囊的药理作用和临床应用浅析.云南中医杂志,1995.1 6(1):5
[50]林祖贤.三七粉治疗前列腺增生肥大[J].实用中西医结合杂志,1994,7(12):753-754
[51]吴茗士.可用来治疗良性前列腺增生肥大没药属植物提取物[J].[英]CPI(B),1994,(9401):98-99
[52]Patevieh D.仙人掌治疗前列腺肥大[J].J Herb SpiceMedplant,1993,2(1):45-49
[53]吉田恭子.以睾酮5-还原酶抑制作用为指标筛选对前列腺肥大有效的生药[J].国外医学·中医中药分册,1998,20(3):57.
[54]Andro M.Carilla E.Pygeum africanum extract for the treatmentof patients with benign prostatic hyperplasia:A reriew of 25years of published experience.CURR THER RES CI IN EXP,1995,56(8):796
[55]Waner B.TransDlantantation of human benign hyperplasiaprostate tissue into nude mice:first result of systemic therapy.UROI INT.1992,48(2):167
[56]曹志明,马鞭草治疗前列腺增生症[J].中医杂志,2001,42(7):393.
[57]王长海.穿山甲治疗前列腺肥人、肾盂结石[J].中医杂志,2002,43(4):254.
[58]俞庆福,周虎,涂怀军,等.前列消煎保留灌肠治疗前列腺增生症的临床研究[J].现代诊断与治疗,2001,12(6):321.
[59]刘雁,李涛.复方中药保留灌肠治疗前列腺增生.广西中医学院学报,2003,6(1):35 37。
[60]陈树清.中药灌肠治疗前列腺增生临床观察[J].内蒙古中医药,1999(4):14.
[61]李松林,王明礼.启癃汤保留灌肠治疗前列腺增生尿潴留35例[J].陕西中医,1997,18(4):152.
[62]伺金柱,李兰英.辨证取穴论治前列腺增生症[J].针刺研究,2000,25(4):300-301.
[63]肖远辉.温针灸为主治疗前列腺增生症疗效观察[J].天津中医学院学报,2002,21(1):20.
[64]杨焱,陈红涛.针刺治疗前列腺增生60例分析[J].实用中医内科杂志,2004,18(3):269--270.
[65]陈鑫,项红.梅花磁针灸疗法治疗良性前列腺增生症临床观察[J].中华现代中西医杂志,2003,1(2):114-116.
[66]张健,王爱平,李淑蓉,等.前列腺热疗后尿潴留的针刺治疗[J].针灸临床杂志,1998,14(12):13-14.
[67]张朋波.针刺治疗癃闭50例[J].针灸临床杂志,1997,(12):17
[68]孙广全,徐红,韩旭艳,等.神阙温灸贴治疗前列腺增生116例[J].辽宁中医杂志,2003,30(9):752,
[69]吕善东.中药敷脐疗法对良性前列腺增生患者症状的影响.中华实用中西医杂志,2004,4(17):2116-2117。
[70]吴乃桐.神阙穴敷贴治疗前列腺肥大36例.上海针灸杂志,1994.13(3):117.
[71]黄慧恒.敷脐疗法治疗老年性前列腺肥大31例.福建中医药,1995,(5):23.
[72]陈志强.中医临床诊治男科专病[M].北京:人民卫生出版社,2000.110-113.
[73]胡猷国.前列腺肥大该注意啥[J].医药与保健,2000(9):36.
[74]周纯芳,谢感共.按摩足部反射区治疗前列腺增生2例[J].中国民间疗法,2003,11(6):20.
[75]赵德成,赵艳霞.黄芪注射液治疗前列腺增生症疗效观察,现代中西医结合杂志,200514(11):1442
[76]成喜雨,郭斌等.肉苁蓉研究进展,天然产物研究与开发,2005,17(2):235-241.
[77]He w(何伟),Zeng GZ(宗桂珍),WU GL(武桂兰),et.Study of valid components in enhancingsex potency.J Chin Med(中国中药杂志),1996,21(9):564-565
[78]李秀掸,何光星,黄霞,等.益肾固泉液抗前列腺增生及 痉作用研究[J].生理科学杂志,2000,22(3):25-28.
[79]刘会亚,张静,宋延平,等.复方贝龙灌肠液对前列腺增生的实验研究[J].西北药学杂志,2002,17(6):255-256.
[80]卢太坤,欧阳洪根等.鳖甲泽兰汤治疗良性前列腺增生症临床观察,四川中医,2005,23(9):59,60.
[81]马骏,任远,金辉,等.前列安对前列腺增生和前列腺炎的抑制作用[J].甘肃中医学院学报,2002,19(1):13-17.
[82]黄小波,李宗信,李斌,等.消癃合剂对丙酸睾丸酮诱发小鼠前列腺增生作用的研究[J].北京中医药大学学报,2002.25(6):37-39.
[83]叶加,李长龄,吴恩融,等.IPH抗实验性前列腺增生的研究[J].中国药学杂志,2002,37(12):906-910.
[84]马清钧.李宏杰,孙曙光,等.干列安胶囊对肾阳亏虚型前列腺增生症影响的研究[J].中医药学刊,2003,21(4):530-531.
[85]廖泽云,邓丽群,黄德彬,等.前列冲剂对大鼠前列腺增生影响的实验研究[J].湖北民族学院学报·医学版,2004,21(3):16-18.
[86]Bravo R,Frank P,BlundeH DA,et al.Cyclin/PCNA isthe auxiliary,prostenoi of DNA Ploymerasa[J].Nature1987,326(5):515.
[87]许国振,崔金涛,严启伟,等.决闭胶囊抗实验性前列腺增生的研究[J].中成药,2001,23(10):735-737.
[88]米振国,刘素香,曹永勤,等.益气通淋冲剂对大鼠前列腺增生组织生长因子的调节作用[J].中国中药杂志,2003,28(7):653-655.
[89]曹继刚,周安方.仙甲汤对前列腺增生大鼠前列腺组织ECF,TGF-B表达影响的研究[J].中医药学刊,2004,22(9):1661-1662.
[90]潘建刚,刘俊生.国外医学泌尿系统分册,前列腺增生症的病因学及新进,2004,24(2):194-197
[91]Orui H,imaizumi S,OginoT,et al.Effects ofbo ne morphogenetic protein-2 on human tumor cell growth and differentiation:a preliminary report.J Orthop Sci,2000,5(6):600-604
[92]Grishina IB,Kim SY,Ferrara C,et al.Dev Biol 2005,288(2):334-347.
[93](a)Planta Med.1994,41,992:
(b)Tetrahedron Lett.1994,35,9593;
(c)Tetrahedron 1995,51,5987
(d)Tetrahedron.1995,51,6003;
(e)J.Nat.Prod.1997,60,216;
(f)Med.Chem.1997,5,631.
(g)Med.Chem.2006,16,4458.
[94]Koik K,Jia Z,Nikaido T.Triterpenoid saponins from vaccaria segetalis(J].Phytochemistry,1998,47:1343.
[95]Jia Z,Kaike K,Kudo M,Triterpenoid saponins and sapogenins from vaccaria segetaliS(J].Phytochemistry,1998,48:529.
[96]桑圣民,劳爱娜,王洪诚.王不留行成分的研究[J].天然产物研究与开发,1998,10:1.
[97]Sang SM,Lao AN,Wang HC.Triterpenoid saponin~from Vaccaria segetais(J].J Asian Nat Prod Res,1999,1:199.
[98]Sang SM,Lao AN,Wang HC.Aphenlpropanoid glycoside from Vaccaria segetalis(J].Phytochemistry,1998,48:569.
[99]Sa ng SM,Lao AN,Wang HC.Triterpenoid saponins from Vaccariasegetais(J].Nat Prod Sci,1998,4:268.
[100]曹继刚,周安方.仙甲汤对前列腺增生大鼠前列腺细胞调亡率影响的实脸研究[J].中国中医药科技,2005,12(1):39.
[101]明.李时珍着.本草纲目.校点本上册.北京:人民卫生出版社,1982.1330-1331.
[102]广东中药志编辑委员会.广东中药志.第一卷.广州:广东科技出版社,1994.453.
[103]江苏新医学院.中药大辞典.下册.上海:上海科学技术出版社.1985.2651-2652.
[104]邓柏杨,崔学教.“异病同治”刍议前列腺增生症的研究思路[J].陕西中医,2008,(4):470-471
[105]崔学教.以瘀阻气虚论治前列腺增生症的思路与方法[J].中国中医基础医学杂志,2001,7(7):48
[106]崔学教,王玺坤,丘振文.良性前列腺增生症的辨证论治[J].新中医,2002,34(4):3
[107]王毅,邵继春,张蜀武.雄激素致大鼠前列腺增生的组织形态学研究[J].中华男科学,2002:8(3):190-193
[108]陈铭,王峻,彭战英,等.益肾补气通瘀法治疗良性前列腺增生症63例[J].四川中医,2005,23(11):51-52
[109]邱云桥,邓春华,谢建兴,等.益肾通对BPH膀胱逼尿肌收缩力影响的临床研究[J].新中医,2004,36(9):20-21
[110]徐发彬,李洪杰,崔学教,等.益肾通方对大鼠慢性膀胱颈梗阻模型逼尿肌组织形态学的影响[J].中国中西医结合外科杂志,2004,10(5):367-369
[111]徐发彬,李洪杰,崔学教,等.益肾通方对大鼠前列腺增生模型的影响[J].新中医,2004,36(10):75-76
[112]付杰新.良性前列腺增生症的膀胱逼尿肌功能异常研究[J].广西医 学.2004.026(005).698-699
[113]Chien CT,Yu HJ,Lin TB,et al,Neural mechanisms of impaired micturition reflex in rats with acute partial bladder outlet obstruction.Neuro-science,2000,96(1):221-230..
[114]杨进益,叶林,侯旭,等.前列腺增生症患者膀胱逼尿肌超微结构的研究.临床泌尿外科杂志.2004.19(001):34-35
[115]刘彝,郑宝钟,等.前列腺增生症所致膀胱出口梗阻患者逼尿肌中神经生长因子mRNA的变化及意义[J].中华泌尿外科杂志.2004.42(14):874-876
[116]杨卫民,张克斌,李光昭.前列腺增生症尿流动力学及膀胱逼尿肌超微结构改变[J].广东医学.2004.25(7):860-862.
[117]卢根生,宋波,等.BPH病人的逼尿肌超微结构观察[J]中华男科学.2002.8(4).283-285
[118]邱功阔.膀胱出口梗阻对逼尿肌功能的影响[J].国外医学.泌尿系统分册,2001,21(5):206-208.
[119]邓春华,郑克立,梅骅.前列腺增生症引起的膀胱逼尿肌功能变化[J].中华泌尿外科杂志.1997.18(2):116-118.
[120]Van der Loop FTL,Schaart G,Timmer EDJ,et al.Smoothelin,a novel cytoskeletal protein specific for smooth muscle cells[J].J Cell Bio1,1996,134:401-411.
[121]牛远杰,马腾骧,白景文,等.去势犬对前列腺基质平滑肌细胞的影响及其临床意义[J].中华泌尿外科杂志.2002.21(4):221.
[122]崔学教.补气益肾祛瘀法治疗前列腺增生58例[J].中医杂志.1994.35(4):22.
[123]崔学教,王玺坤,丘振文.良性前列腺增生症的辨证论治[J].新中医,2002,34(4):3-4.
[124]韩丽华,王和,孙佩杰,等.肽类生长因子与前列腺增生[J].沈阳医学院学报.2004.6(2).118-120.
[125]陈芷玲.肾虚与妇女更年期[J].苏州医学院学报,1998,18(5):499.
[126]程军平.前列腺解剖位置观察及经直肠局部药物注射治疗慢性前列腺炎临床分析[J].第一军医大学学报,2003.23(6):633-635
[127]王军.活血化瘀法治疗前列腺增生症36例疗效观察[J].宁夏医学院学报,2000.22(3):219-231.
[128]徐发彬,李洪杰,谢建兴,等.益肾通方对大鼠慢性膀胱颈梗阻模型逼尿肌组织形态学的 影响[J].中国中西医结合外科杂志.2004.1.(5):27-29.
[129]丁兆梦.中药药效与临床[M].中国医药科技出版社.1999:183.
[130]Morita H,et al.Thionation of segetalins A and B,cyclic peptides with estrogen-like activey from seeds of Vaccaria segetalis[J].Bioorg Med Chem,1997,5(3):631
[131]郭敏一.王不留行是一种有希望的避孕药物[J].中医药学报,1998,(3):49.
[132]何慧德.加强老年流行病学研究,迎接人口老龄化的到来[J].中华老年医学杂志,1996.15(6):323
[132]《全国中草药汇编》编写组.全国中草药汇编(上册)[M].第一版,北京,人民卫生出版社,1975,68
[133]Mattiasson A,Uvelius B.Changes in contractile properities in hypertrophic rat urinary bladder[J].J.Urology,1982,128:134.
[134]JA,Chang S,膀胱出口部分梗阻(PB00)引起逼尿肌肥大、收缩力降低及逼尿肌收缩和调控蛋白的改变[J]Hypolite,et al.J Urol,2006,175(2):7772882.
[135]王杭,膀胱出口梗阻引起逼尿肌肌球蛋白重链亚型表达改变的实验研究,Chin J Urol,July 2005,26,(7):458-459
[136]李文刚,急性尿潴留大鼠膀胱功能损害与组织结构改变的关系[J].第三军医大学学报2006.28,(8)823
[137]白志明,膀胱出口梗阻后逼尿肌收缩蛋白表达和膀胱重量的改变[J].Chinese Journal of Andrology 2007.21.(8)14-15
[138]Mannikarottu AS,膀胱出口部分梗阻(PB00)引起平滑肌肌球蛋白亚型表达的区域差异[J].Journal of Urol,2005,173(1):3022308.
[2]徐积恩.良性前列腺增生治疗药依普甾胺(Epristeride).国外医学·合成药、生化药制剂分册.1995.16(4):240
[3]焦安钦,前列腺增生症病机特点与治疗思路贵阳中医学院学报,1996:18(4):4
[4]周家珩.扶正化瘀法治疗前列腺增生症135例 江苏中医,1991;12(3):115
[5]杜英博.冯老治疗老年病经验点滴 实用中医内科杂志,1992:6(4):184
[6]何清湖.前列腺增生症肾虚血瘀病机探讨 湖南中医学院学报,1997:17(2)8-10
[7]祁公任,陈涛.前列腺增生症中医病机证治观[J].江苏中医,1998,19(11):16
[8]焦安钦.前列腺增生症病机特点与治疗思路[J].贵阳中医学院学报,1996,18(4):4
[9]林君玉.85例前列腺肥大症临床经验[J].江苏中医,1990,11(11):494
[10]张缃,卡金梅,王娟娥.中西医结合治疗老年前列腺良性肥大急性尿潴留[J].山西医学院学报,1993,4(2):231
[11]周家珩.扶正化痰法治疗前列腺增生症135例[J].江苏中医,1991,12(3):115
[12]杜英博.冯老治疗老年病经验点滴[J].实用中医内科杂志,1992,6(4):184
[13]张锡君.对老年前列腺肥大防治的体会[J].中医杂志,1986,27(5):330
[14]吴光明,魏秋关.清热利湿化瘀法治疗前列腺肥大33例[J].湖南中医杂志,1993,9(3):36
[15]何红兵,从瘀辨证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3):181。
[16]韦淑平,鞠祥宗.益肾通癃方治疗前列腺增生50例[J].陕西中医,2002,23(4):317.
[17]谢嘉文,沈自尹,王文健,等.补肾益元法与化瘀散结法治疗前列腺肥大症的临床研究[J].中国中西医结合杂志,1994,14(9):519
[18]张亚大,卢子杰,张平,黄树纲.益肾逐瘀汤治疗前列腺增生症30例观察[J].南京中医药大学学报(自然科学版),2001,17(4):216.
[19]张关荣.从瘀辨治前列腺增生症52例[J]、四川中医,1998.16(3):24.
[20]胡臻.升阳通络汤治疗前列腺增生症20例[J].中国中医药信息杂志,2002,9(9):53
[21]蓝毕生.通补奇经方治疗良性前列腺增生症32例[J].吉林中医药,2002,22(3)19.
[22]郭明福.“开利散结汤”治疗前列腺增生110例[J].江苏中医药,2003,2 4(3):34.
[23]赵建业.戴春福教授以活血法治疗前列腺增生症经验[J].福建中医药,2004,35(2):21-22.
[24]穆惠荣,路继儒.海藻玉壶汤加减治疗前列腺增生症(附26例分析)[J].医学理论与实践,2003,16(6):674.
[25]赵跃红.加味壮元汤治疗前列腺增生症62例[J]湖南中医杂志,2004,20(3):54.
[26]崔学教,王玺坤,丘振文.良性前列腺增生症的辨证论治[J].新中医,2002,34(4):3-4.
[27]德永固三.前列腺增生的汉方治疗[J].国外医学·中医中药分册,1997,19(4):41-44
[28]尹国良,李世平,邵俊.前列腺增生症的辨治体会[J]湖北中医杂志,2003,25(9):21.22.
[29]曹继刚,段臀志.辨证分型治疗前列腺增生93例疗效观察[J].云南中医中药杂志,2003,24(2):21.
[30]王劲松.自拟癃闭方治疗前列腺增生症50例[J].国医论坛,1997,12(1):32-34
[31]吴敬农.补敛提汤治疗老年前列腺肥大症64例[J].江苏中医,1996,17(1):17-18
[32]马华.癃闭通治疗老年前列腺增生症临床疗效观察[J].中医药研究,1996,16(2):29-30
[33]张庆好.启癃汤治疗老年前列腺肥大症55例[J].新中医,1995,27(2):23-24
[34]张云程.中药治疗前列腺增生症90例[J].成都中医学院学报,1991,(13):16-18
[35]姚德鸿.前列腺增生症[M].上海:上海医科大学出版社,1993.56
[36]梁永,董杨颖,张妍燕.肩闭通关汤治疗良性前列腺增生症33例疗效观察[J].河jE中医,2003,25(8):620.622.
[37]姜杰,周健民.中医药疗法治疗前列腺增生症80例临床观察[J].长春中医学院学报。2003,19(2):19.
[38]欧亚龙,杨光,下红静.消积通关汤治疗前列腺增生症62例疗效观察[J].四川中医,2004,22(6):49.51.
[39]宋晓鸿,陈氏前列安治疗前列腺增生症73例疗效观察[J].青海医药杂志,2004,34(10):45.46.
[40]李跃庆.宣降益气通癃汤治疗老年前列腺增生42例[J].实用中医内科杂志,2004,18(6):537.
[41]王敬善.前列舒丸治疗前列腺增生症和慢性前列腺炎81例[J].山东中医杂志,1990,9(6):12-13
[42]黄窈勤.前列舒丸的临床疗效观察[J].中成药,1993,15(3):23-24
[43]贾玉森.前列平治疗前列腺增生症的临床观察[J].中国医药学报,1996,16(1):5-7
[44]成爱光.中药注射液静脉滴注治疗前列腺增生症52例[J].上海中医药杂志,1999,(2):18-19
[45]唐涌志.癃闭舒胶囊治疗前列腺增生症的临床观察[J].上海中医药杂志,1999,(2):18-19
[46]金杰.生长因子抑制剂治疗前列腺增生症[J].中华泌尿外科杂志,1997,18(5):293
[47]柯梦笔.前列平治疗前列腺增生症46例.山东中医杂志.1995、14(2):542
[48]段登志.欧阳虹.王寅.等.前列回春胶囊治疗前列腺增生症56例.云南中医杂志.1994.15(6):35
[49]段登志,欧阳虹,王寅.等.前列回春胶囊的药理作用和临床应用浅析.云南中医杂志,1995.1 6(1):5
[50]林祖贤.三七粉治疗前列腺增生肥大[J].实用中西医结合杂志,1994,7(12):753-754
[51]吴茗士.可用来治疗良性前列腺增生肥大没药属植物提取物[J].[英]CPI(B),1994,(9401):98-99
[52]Patevieh D.仙人掌治疗前列腺肥大[J].J Herb SpiceMedplant,1993,2(1):45-49
[53]吉田恭子.以睾酮5-还原酶抑制作用为指标筛选对前列腺肥大有效的生药[J].国外医学·中医中药分册,1998,20(3):57.
[54]Andro M.Carilla E.Pygeum africanum extract for the treatmentof patients with benign prostatic hyperplasia:A reriew of 25years of published experience.CURR THER RES CI IN EXP,1995,56(8):796
[55]Waner B.TransDlantantation of human benign hyperplasiaprostate tissue into nude mice:first result of systemic therapy.UROI INT.1992,48(2):167
[56]曹志明,马鞭草治疗前列腺增生症[J].中医杂志,2001,42(7):393.
[57]王长海.穿山甲治疗前列腺肥人、肾盂结石[J].中医杂志,2002,43(4):254.
[58]俞庆福,周虎,涂怀军,等.前列消煎保留灌肠治疗前列腺增生症的临床研究[J].现代诊断与治疗,2001,12(6):321.
[59]刘雁,李涛.复方中药保留灌肠治疗前列腺增生.广西中医学院学报,2003,6(1):35 37。
[60]陈树清.中药灌肠治疗前列腺增生临床观察[J].内蒙古中医药,1999(4):14.
[61]李松林,王明礼.启癃汤保留灌肠治疗前列腺增生尿潴留35例[J].陕西中医,1997,18(4):152.
[62]伺金柱,李兰英.辨证取穴论治前列腺增生症[J].针刺研究,2000,25(4):300-301.
[63]肖远辉.温针灸为主治疗前列腺增生症疗效观察[J].天津中医学院学报,2002,21(1):20.
[64]杨焱,陈红涛.针刺治疗前列腺增生60例分析[J].实用中医内科杂志,2004,18(3):269--270.
[65]陈鑫,项红.梅花磁针灸疗法治疗良性前列腺增生症临床观察[J].中华现代中西医杂志,2003,1(2):114-116.
[66]张健,王爱平,李淑蓉,等.前列腺热疗后尿潴留的针刺治疗[J].针灸临床杂志,1998,14(12):13-14.
[67]张朋波.针刺治疗癃闭50例[J].针灸临床杂志,1997,(12):17
[68]孙广全,徐红,韩旭艳,等.神阙温灸贴治疗前列腺增生116例[J].辽宁中医杂志,2003,30(9):752,
[69]吕善东.中药敷脐疗法对良性前列腺增生患者症状的影响.中华实用中西医杂志,2004,4(17):2116-2117。
[70]吴乃桐.神阙穴敷贴治疗前列腺肥大36例.上海针灸杂志,1994.13(3):117.
[71]黄慧恒.敷脐疗法治疗老年性前列腺肥大31例.福建中医药,1995,(5):23.
[72]陈志强.中医临床诊治男科专病[M].北京:人民卫生出版社,2000.110-113.
[73]胡猷国.前列腺肥大该注意啥[J].医药与保健,2000(9):36.
[74]周纯芳,谢感共.按摩足部反射区治疗前列腺增生2例[J].中国民间疗法,2003,11(6):20.
[75]赵德成,赵艳霞.黄芪注射液治疗前列腺增生症疗效观察,现代中西医结合杂志,200514(11):1442
[76]成喜雨,郭斌等.肉苁蓉研究进展,天然产物研究与开发,2005,17(2):235-241.
[77]He w(何伟),Zeng GZ(宗桂珍),WU GL(武桂兰),et.Study of valid components in enhancingsex potency.J Chin Med(中国中药杂志),1996,21(9):564-565
[78]李秀掸,何光星,黄霞,等.益肾固泉液抗前列腺增生及 痉作用研究[J].生理科学杂志,2000,22(3):25-28.
[79]刘会亚,张静,宋延平,等.复方贝龙灌肠液对前列腺增生的实验研究[J].西北药学杂志,2002,17(6):255-256.
[80]卢太坤,欧阳洪根等.鳖甲泽兰汤治疗良性前列腺增生症临床观察,四川中医,2005,23(9):59,60.
[81]马骏,任远,金辉,等.前列安对前列腺增生和前列腺炎的抑制作用[J].甘肃中医学院学报,2002,19(1):13-17.
[82]黄小波,李宗信,李斌,等.消癃合剂对丙酸睾丸酮诱发小鼠前列腺增生作用的研究[J].北京中医药大学学报,2002.25(6):37-39.
[83]叶加,李长龄,吴恩融,等.IPH抗实验性前列腺增生的研究[J].中国药学杂志,2002,37(12):906-910.
[84]马清钧.李宏杰,孙曙光,等.干列安胶囊对肾阳亏虚型前列腺增生症影响的研究[J].中医药学刊,2003,21(4):530-531.
[85]廖泽云,邓丽群,黄德彬,等.前列冲剂对大鼠前列腺增生影响的实验研究[J].湖北民族学院学报·医学版,2004,21(3):16-18.
[86]Bravo R,Frank P,BlundeH DA,et al.Cyclin/PCNA isthe auxiliary,prostenoi of DNA Ploymerasa[J].Nature1987,326(5):515.
[87]许国振,崔金涛,严启伟,等.决闭胶囊抗实验性前列腺增生的研究[J].中成药,2001,23(10):735-737.
[88]米振国,刘素香,曹永勤,等.益气通淋冲剂对大鼠前列腺增生组织生长因子的调节作用[J].中国中药杂志,2003,28(7):653-655.
[89]曹继刚,周安方.仙甲汤对前列腺增生大鼠前列腺组织ECF,TGF-B表达影响的研究[J].中医药学刊,2004,22(9):1661-1662.
[90]潘建刚,刘俊生.国外医学泌尿系统分册,前列腺增生症的病因学及新进,2004,24(2):194-197
[91]Orui H,imaizumi S,OginoT,et al.Effects ofbo ne morphogenetic protein-2 on human tumor cell growth and differentiation:a preliminary report.J Orthop Sci,2000,5(6):600-604
[92]Grishina IB,Kim SY,Ferrara C,et al.Dev Biol 2005,288(2):334-347.
[93](a)Planta Med.1994,41,992:
(b)Tetrahedron Lett.1994,35,9593;
(c)Tetrahedron 1995,51,5987
(d)Tetrahedron.1995,51,6003;
(e)J.Nat.Prod.1997,60,216;
(f)Med.Chem.1997,5,631.
(g)Med.Chem.2006,16,4458.
[94]Koik K,Jia Z,Nikaido T.Triterpenoid saponins from vaccaria segetalis(J].Phytochemistry,1998,47:1343.
[95]Jia Z,Kaike K,Kudo M,Triterpenoid saponins and sapogenins from vaccaria segetaliS(J].Phytochemistry,1998,48:529.
[96]桑圣民,劳爱娜,王洪诚.王不留行成分的研究[J].天然产物研究与开发,1998,10:1.
[97]Sang SM,Lao AN,Wang HC.Triterpenoid saponin~from Vaccaria segetais(J].J Asian Nat Prod Res,1999,1:199.
[98]Sang SM,Lao AN,Wang HC.Aphenlpropanoid glycoside from Vaccaria segetalis(J].Phytochemistry,1998,48:569.
[99]Sa ng SM,Lao AN,Wang HC.Triterpenoid saponins from Vaccariasegetais(J].Nat Prod Sci,1998,4:268.
[100]曹继刚,周安方.仙甲汤对前列腺增生大鼠前列腺细胞调亡率影响的实脸研究[J].中国中医药科技,2005,12(1):39.
[101]明.李时珍着.本草纲目.校点本上册.北京:人民卫生出版社,1982.1330-1331.
[102]广东中药志编辑委员会.广东中药志.第一卷.广州:广东科技出版社,1994.453.
[103]江苏新医学院.中药大辞典.下册.上海:上海科学技术出版社.1985.2651-2652.
[104]邓柏杨,崔学教.“异病同治”刍议前列腺增生症的研究思路[J].陕西中医,2008,(4):470-471
[105]崔学教.以瘀阻气虚论治前列腺增生症的思路与方法[J].中国中医基础医学杂志,2001,7(7):48
[106]崔学教,王玺坤,丘振文.良性前列腺增生症的辨证论治[J].新中医,2002,34(4):3
[107]王毅,邵继春,张蜀武.雄激素致大鼠前列腺增生的组织形态学研究[J].中华男科学,2002:8(3):190-193
[108]陈铭,王峻,彭战英,等.益肾补气通瘀法治疗良性前列腺增生症63例[J].四川中医,2005,23(11):51-52
[109]邱云桥,邓春华,谢建兴,等.益肾通对BPH膀胱逼尿肌收缩力影响的临床研究[J].新中医,2004,36(9):20-21
[110]徐发彬,李洪杰,崔学教,等.益肾通方对大鼠慢性膀胱颈梗阻模型逼尿肌组织形态学的影响[J].中国中西医结合外科杂志,2004,10(5):367-369
[111]徐发彬,李洪杰,崔学教,等.益肾通方对大鼠前列腺增生模型的影响[J].新中医,2004,36(10):75-76
[112]付杰新.良性前列腺增生症的膀胱逼尿肌功能异常研究[J].广西医 学.2004.026(005).698-699
[113]Chien CT,Yu HJ,Lin TB,et al,Neural mechanisms of impaired micturition reflex in rats with acute partial bladder outlet obstruction.Neuro-science,2000,96(1):221-230..
[114]杨进益,叶林,侯旭,等.前列腺增生症患者膀胱逼尿肌超微结构的研究.临床泌尿外科杂志.2004.19(001):34-35
[115]刘彝,郑宝钟,等.前列腺增生症所致膀胱出口梗阻患者逼尿肌中神经生长因子mRNA的变化及意义[J].中华泌尿外科杂志.2004.42(14):874-876
[116]杨卫民,张克斌,李光昭.前列腺增生症尿流动力学及膀胱逼尿肌超微结构改变[J].广东医学.2004.25(7):860-862.
[117]卢根生,宋波,等.BPH病人的逼尿肌超微结构观察[J]中华男科学.2002.8(4).283-285
[118]邱功阔.膀胱出口梗阻对逼尿肌功能的影响[J].国外医学.泌尿系统分册,2001,21(5):206-208.
[119]邓春华,郑克立,梅骅.前列腺增生症引起的膀胱逼尿肌功能变化[J].中华泌尿外科杂志.1997.18(2):116-118.
[120]Van der Loop FTL,Schaart G,Timmer EDJ,et al.Smoothelin,a novel cytoskeletal protein specific for smooth muscle cells[J].J Cell Bio1,1996,134:401-411.
[121]牛远杰,马腾骧,白景文,等.去势犬对前列腺基质平滑肌细胞的影响及其临床意义[J].中华泌尿外科杂志.2002.21(4):221.
[122]崔学教.补气益肾祛瘀法治疗前列腺增生58例[J].中医杂志.1994.35(4):22.
[123]崔学教,王玺坤,丘振文.良性前列腺增生症的辨证论治[J].新中医,2002,34(4):3-4.
[124]韩丽华,王和,孙佩杰,等.肽类生长因子与前列腺增生[J].沈阳医学院学报.2004.6(2).118-120.
[125]陈芷玲.肾虚与妇女更年期[J].苏州医学院学报,1998,18(5):499.
[126]程军平.前列腺解剖位置观察及经直肠局部药物注射治疗慢性前列腺炎临床分析[J].第一军医大学学报,2003.23(6):633-635
[127]王军.活血化瘀法治疗前列腺增生症36例疗效观察[J].宁夏医学院学报,2000.22(3):219-231.
[128]徐发彬,李洪杰,谢建兴,等.益肾通方对大鼠慢性膀胱颈梗阻模型逼尿肌组织形态学的 影响[J].中国中西医结合外科杂志.2004.1.(5):27-29.
[129]丁兆梦.中药药效与临床[M].中国医药科技出版社.1999:183.
[130]Morita H,et al.Thionation of segetalins A and B,cyclic peptides with estrogen-like activey from seeds of Vaccaria segetalis[J].Bioorg Med Chem,1997,5(3):631
[131]郭敏一.王不留行是一种有希望的避孕药物[J].中医药学报,1998,(3):49.
[132]何慧德.加强老年流行病学研究,迎接人口老龄化的到来[J].中华老年医学杂志,1996.15(6):323
[132]《全国中草药汇编》编写组.全国中草药汇编(上册)[M].第一版,北京,人民卫生出版社,1975,68
[133]Mattiasson A,Uvelius B.Changes in contractile properities in hypertrophic rat urinary bladder[J].J.Urology,1982,128:134.
[134]JA,Chang S,膀胱出口部分梗阻(PB00)引起逼尿肌肥大、收缩力降低及逼尿肌收缩和调控蛋白的改变[J]Hypolite,et al.J Urol,2006,175(2):7772882.
[135]王杭,膀胱出口梗阻引起逼尿肌肌球蛋白重链亚型表达改变的实验研究,Chin J Urol,July 2005,26,(7):458-459
[136]李文刚,急性尿潴留大鼠膀胱功能损害与组织结构改变的关系[J].第三军医大学学报2006.28,(8)823
[137]白志明,膀胱出口梗阻后逼尿肌收缩蛋白表达和膀胱重量的改变[J].Chinese Journal of Andrology 2007.21.(8)14-15
[138]Mannikarottu AS,膀胱出口部分梗阻(PB00)引起平滑肌肌球蛋白亚型表达的区域差异[J].Journal of Urol,2005,173(1):3022308.